Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hurteloup

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Bulletin Du Cancer|January 1, 1980
[News from the French cancer registry of Doubs (author's transl)]S Schraub, P Hurteloup, P hurteloup, et al.
Pharmacoeconomics|April 7, 1997
Cost utility in second-line metastatic breast cancerG Berdeaux, P Hurteloup
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|June 1, 1997
The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspectiveG Berdeaux, P Hurteloup
Soins; La Revue De Reference Infirmiere|May 20, 1981
[Rehabilitation of breast cancer patients]S Schraub, P Hurteloup
Revue De L'Infirmiere|November 1, 1981
[Classification of cancers]S Schraub, P Hurteloup
Drugs Under Experimental and Clinical Research|January 1, 1986
Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicinP Hurteloup, F Ganzina
Hematological Oncology|March 1, 1992
Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patientsJ Robert, F Rigal-Huguet, P Hurteloup
Bulletin Du Cancer|January 1, 1981
[Oral morphine in pain for cancer patients : Some major digestive complications]J Y Cahn, P Hurteloup, J F Bosset, et al.
Onkologie|August 1, 1986
[French FAC vs FEC study in advanced breast cancer]R Keiling, P P Armand, P Hurteloup, et al.
Cancer Treatment Reports|April 1, 1983
Phase II clinical evaluation of 4'-epi-doxorubicinP Hurteloup, P Cappelaere, J P Armand, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Bulletin Du Cancer|January 1, 1980
[News from the French cancer registry of Doubs (author's transl)]S Schraub, P Hurteloup, P hurteloup, et al.
Pharmacoeconomics|April 7, 1997
Cost utility in second-line metastatic breast cancerG Berdeaux, P Hurteloup
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|June 1, 1997
The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspectiveG Berdeaux, P Hurteloup
Soins; La Revue De Reference Infirmiere|May 20, 1981
[Rehabilitation of breast cancer patients]S Schraub, P Hurteloup
Revue De L'Infirmiere|November 1, 1981
[Classification of cancers]S Schraub, P Hurteloup
Drugs Under Experimental and Clinical Research|January 1, 1986
Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicinP Hurteloup, F Ganzina
Hematological Oncology|March 1, 1992
Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patientsJ Robert, F Rigal-Huguet, P Hurteloup
Bulletin Du Cancer|January 1, 1981
[Oral morphine in pain for cancer patients : Some major digestive complications]J Y Cahn, P Hurteloup, J F Bosset, et al.
Onkologie|August 1, 1986
[French FAC vs FEC study in advanced breast cancer]R Keiling, P P Armand, P Hurteloup, et al.
Cancer Treatment Reports|April 1, 1983
Phase II clinical evaluation of 4'-epi-doxorubicinP Hurteloup, P Cappelaere, J P Armand, et al.
Pageof 4